Plain-English translation of NCT06034938 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new HIV medication combination called Doravirine/Tenofovir/Lamivudine (or Delstrigo) in people living with HIV whose virus is currently well-controlled but who have a specific type of resistance to one of their current drugs. The researchers want to see if this medication can keep the virus suppressed for at least 24 weeks and potentially longer, while also being easier to tolerate.
Many people with HIV develop resistance to certain medications over time, which limits their treatment options. This trial exists to find out whether this new medication combination might work well for people who have developed this specific type of resistance but whose virus remains suppressed—potentially giving them a simpler, more effective alternative to their current regimen.
You likely qualify if…
You likely don't qualify if…
You would switch from your current HIV medications to a single daily pill containing the three-drug combination and take it for 48 weeks. During this time, you'll have regular blood tests to monitor your HIV levels and check for any changes—starting at 24 weeks and continuing through week 48. The researchers will also track any changes in your weight, metabolism, and HIV resistance patterns to see how well the medication works and how your body tolerates it.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
France